Cargando…

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

Detalles Bibliográficos
Autores principales:	Linton, Kim, Forconi, Francesco, Lewis, David, Riches, John, El-Sharkawi, Dima, Gleeson, Mary, Injac, Sarah G, Nandakumar, Srinand, Tan, May, Cherala, Ganesh, Collins, Graham P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428929/ http://dx.doi.org/10.1097/01.HS9.0000975912.59317.8d

Ejemplares similares

PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
por: Linton, Kim, et al.
Publicado: (2023)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

A covalent BTK ternary complex compatible with targeted protein degradation
por: Schiemer, James, et al.
Publicado: (2023)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function
por: Trory, Justin S., et al.
Publicado: (2022)

PB1874: BTK GENE MUTATIONS IN RUSSIAN PATIENTS TREATED WITH IBRUTINIB: AS-PCR VERSUS NGS FOR ALLELIC LOAD ASSESSMENT
por: Likold, E., et al.
Publicado: (2022)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma
por: Yeh, Chi-Tai, et al.
Publicado: (2021)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
por: Strijbis, Karin, et al.
Publicado: (2013)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
por: Sala, Luca, et al.
Publicado: (2019)

Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome
por: Wang, Guang, et al.
Publicado: (2022)

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS
por: Macwan, Joyce, et al.
Publicado: (2023)

P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS
por: Wang, Haitao, et al.
Publicado: (2023)

PB1943: THE EFFECTS OF AN ONLINE CURRICULUM BASED APPROACH TO CME ON HEMATOLOGIST/ONCOLOGISTS’ ABILITY TO TREAT PATIENTS WITH BTK INHIBITORS FOR B-CELL MALIGNANCIES
por: Bomba, Sarah Elizabeth, et al.
Publicado: (2023)

A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
por: Zheng, Bixia, et al.
Publicado: (2014)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

PB2296: THE PROGNOSTIC ROLE OF NEUTROPHIL TO LYMPHOCYTE RATIO AND PLATELET TO LYMPHOCYTE RATIO IN COVID-19 PATIENTS: A MONOCENTRIC STUDY
por: Boufrikha, W., et al.
Publicado: (2022)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h75t8kgs77dish74m516sqnglv